The healthcare sector is staging a notable comeback, with pharmaceutical and biotech equities attracting renewed investor interest.
This rotation marks a shift in market sentiment, as capital moves away from the technology sector, which has dominated headlines with artificial intelligence leaders like Nvidia.
While tech stocks have drawn the most attention, healthcare has been quietly recovering from a prolonged period of underperformance.
Funds focused on life sciences, such as the Janus Henderson Global Life Sciences fund, are benefiting from this trend.
The inflows suggest that investors are seeking diversification and stability, viewing healthcare as a haven amid the volatility of tech-heavy portfolios.
This rotation is not isolated; broader market data indicates that healthcare stocks are increasingly seen as a safe harbor for those reducing exposure to high-growth tech names.